Seminars in Oncology
Volume 36, Issue 2 , Pages 126-136 , April 2009

Ovarian Stromal and Germ Cell Tumors

  • Carolyn R. Koulouris
    • ,
  • Richard T. Penson

      Affiliations

    • Corresponding Author InformationAddress correspondence to Richard T. Penson, MD, MRCP, Division of Hematology Oncology, Massachusetts General Hospital, Yawkey 9066, 32 Fruit St, Boston, MA 02114

References 

  1. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol. 2005;97:519–523
  2. Rosenberg B. Possible mechanisms for the antitumor activity of platinum coordination complexes. Cancer Chemother Rep. 1975;59:589–598
  3. Garner MJ, Turner MC, Ghadirian P, Krewski D. Epidemiology of testicular cancer: an overview. Int J Cancer. 2005;116:331–339
  4. Stettner AR, Hartenbach EM, Schink JC, Huddart R, Becker J, Pauli R, et al. Familial ovarian germ cell cancer: report and review. Am J Med Genet. 1999;84:43–46
  5. Smith H, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107:1075–1085
  6. Michala L, Goswami D, Creighton SM, Conway GS. Swyer syndrome: presentation and outcomes. BJOG. 2008;115:737–741
  7. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007;25:2938–2943
  8. Young RH. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol. 2005;18:S81–S98
  9. Shumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21:1180–1189
  10. Zhang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng N, et al. Prognostic factors in sex cord stromal tumors of the ovary—an analysis of 376 women. Gynecol Oncol. 2007;104:396–400
  11. La Vecchia C, Morris HB, Draper GJ. Malignant ovarian tumours in childhood in Britain, 1962-78. Br J Cancer. 1983;48:363
  12. You W, Dainty LA, Rose GS, Krivak T, McHale MT, Olsen CH, et al. Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol. 2005;105:1405–1409
  13. Gordon A, Lipton D, Woodruff JD. Dysgerminoma: a review of 158 cases from the Emil Novak ovarian tumor registry. Obstet Gynecol. 1981;58:497
  14. Song ES, Lee JP, Han JH, Kim HY, Mun SH, Ryu HS, et al. Dysgerminoma of the ovary with precocious puberty: a case report. Gynecol Endocrinol. 2007;23:34–37
  15. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005;18:651–679
  16. Goswami D, Sharma K, Zutshi V, Tempe A, Nigam S. Nongestational pure ovarian choriocarcinoma with contralateral teratoma. Gynecol Oncol. 2001;80:262–266
  17. Yarris JP, Hunter AJ. Roy Hertz, M.D. (1909-2002): the cure of choriocarcinoma and its impact on the development of chemotherapy for cancer. Gynecol Oncol. 2003;89:193–198
  18. Atkin NB, Baker MC. i(12p): specific chromosomal marker in seminoma and malignant teratoma of the testis?. Cancer Genet Cytogenet. 1983;10:199
  19. Cossu-Rocca P, Zhang S, Roth LM, Eble JN, Zheng W, Karim FW, et al. Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis. Mod Pathol. 2006;19:611–615
  20. Poulos C, Cheng L, Zhang S, Gersell DJ, Ulbright TM. Analysis of ovarian teratomas for isochromosome 12p: evidence supporting a dual histogenetic pathway for teratomatous elements. Mod Pathol. 2006;19:766–771
  21. Bussey KJ, Lawce HJ, Olson SB, Arthur DC, Kalousek DK, Krailo M, et al. Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences—a Children's Cancer Group study. Genes Chromosomes Cancer. 1999;25:134–146
  22. Patterson DM, Rustin GJ. Controversies in the management of germ cell tumours of the ovary. Curr Opin Oncol. 2006;18:500–506
  23. di Pietro A, Vries EG, Gietema JA, Spierings DC, de Jong S. Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumors. Int J Biochem Cell Biol. 2005;37:2437–2456
  24. Oliver RT. Germ Cell Cancer. Curr Opin Oncol. 1999;11:236–241
  25. Talerman A, Haije WG, Baggerman L. Serum alphafetoprotein (AFP) in patients with germ cell tumors of the gonads and extragonadal sites: correlation between endodermal sinus (yolk sac) tumor and raised serum AFP. Cancer. 1980;46:380–385
  26. Garcia-Campayo V, Boime I. Independent activities of FSH and LH structurally confined in a single polypeptide: selective modification of the relative potencies of the hormones. Endocrinology. 2001;142:5203–5211
  27. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III randomized trail of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–256
  28. Lai CH, Chang TC, Hsueh S, Wu TI, Chao A, Chou HH, et al. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol. 2005;784–791
  29. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S FIGO Committee on Gynecological Oncology. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet. 2000;70:209–262
  30. Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006;24:4862–4866
  31. Kurman RJ, Norris HJ. Malignant germ cell tumors of the ovary. Hum Pathol. 1977;8:551–564
  32. Low JJ, Perrin LC, Crandon AK, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors, a review of 77 cases. Cancer. 2000;89:391–398
  33. Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecological Oncology Group study. J Clin Oncol. 2007;25:2792–2797
  34. El-Lamie IK, Shehata NA, Abou-Loz SK, El-Lamie KI. Conservation surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University. Eur J Gynaecol Oncol. 2000;21:605–609
  35. Dark GG, Bower M, Newlands ES, Paradinas F, Rustin GJ. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol. 1997;15:620–624
  36. Gershenson DM. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr. 2005;34:43–47
  37. Chan JL, Zhang M, Kaleb V, Loizzi V, Benjamin J, Vasilev S, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary—a multivariate analysis. Gynecol Oncol. 2005;96:204–209
  38. Evans AT, Gaffey TA, Malkasian GD, Annegers JF. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol. 1980;55:231–238
  39. Colombo N, Parma G, Zanagnolo V, Insigna A. Management of ovarian stromal cell tumors. J Clin Oncol. 2007;25:2944–2951
  40. Ward-McQuaid JN. Haemoperitoneum following rupture of a granulosa-cell tumour of the ovary. Br J Surg. 1949;37:242–244
  41. Poma PA. Hemoperitoneum in a postmenopausal woman. J Natl Med Assoc. 1998;90:317–319
  42. De Backer A, Madern GC, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW. Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer. 2006;46:459–464
  43. Slayton RE, Park RC, Silverberg SG, Shingleton H, Creasman WT, Blessing JA. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: a Gynecologic Oncology Group study (a final report). Cancer. 1985;56:243–248
  44. Bafna UD, Umadevi K, Kumaran C, Nagarathna DS, Shashikala P, Tanseen R. Germ cell tumours of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors?. Int J Gynecol Cancer. 2001;11:300–304
  45. Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, et al. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2008;8:766–794
  46. Gershenson DM, Copeland LJ, Kavanagh JJ, Stringer CA, Saul PB, Wharton JT. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin and cyclophosphamide. Obstet Gynecol. 1987;7:765–769
  47. Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecological Oncology Group study. Gynecol Oncol. 1999;72:131–137
  48. Brown J, Shvartsman HS, Deavers MT, Burke TW, Munsell MF, Gershenson DM. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol. 2004;22:3517–3523
  49. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol. 1998;16:1297-93
  50. Williams S, Blessing JA, Liao S, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994;12:701–706
  51. de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19:1629–1640
  52. Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors (A trial of the Gynecological Oncology Group). Ann Intern Med. 1989;111:22–27
  53. Chen J, Stubbe J. Bleomycins: toward better therapeutics. Nat Rev Cancer. 2005;5:102–112
  54. Bower M, Fife K, Holden L, Paradinas FJ, Rustin GJ, Newlands ES. Chemotherapy for ovarian germ cell tumours. Eur J Cancer. 1996;32A:593–597
  55. Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol. 1996;14:1106–1113
  56. Kondagunta GV, Bacik J, Bajorin D, Dobrzynski D, Sheinfeld J, Motzer RJ, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol. 2005;23:9290–9294
  57. Bokemeyer C, Kohrmann O, Tischler J, Weissbach L, Rath U, Haupt A, et al. A randomized trial of cisplatin, etoposide, bleomycin (PEB) versus carboplatin, etoposide, bleomycin (CEB) for patients with ‘good risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol. 1996;7:1015–1021
  58. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol. 1993;11:598–606
  59. Horwich A, Sleijfer D, Fossa SD, Kaye SB, Oliver RT, Cullen MH, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol. 1997;15:1844–1852
  60. Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol. 2000;18:3808–3818
  61. Williams SD, Blessing JA, Hatch KD, Homesley HD. Chemotherapy of advanced dysgerminoma: trials of the Gynecological Oncology Group. J Clin Oncol. 1991;9:1950–1955
  62. Krege S, Kalund G, Otto T, Goepel M, Rubben H. Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol. 1997;31:405–407
  63. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet. 2005;366:293–300
  64. Williams SD, Kauderer J, Burnett AF, Lentz SS, Aghajanian C, Armstrong DK. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol. 2004;95:496–499
  65. Williams SD, Blessing JA, DiSaia PJ, Major FJ, Ball HG, Liao SY. Second-look laparotomy in ovarian germ cell tumors: the Gynecological Oncology Group experience. Gynecol Oncol. 1994;52:287–291
  66. Hariprasad R, Kumar L, Janga D, Kumar S, Vijayaraghavan M. Growing teratoma syndrome of the ovary. Int J Clin Oncol. 2008;13:83–87
  67. Gershenson DM, Copeland LJ, del Junco G, Edwards CL, Wharton JT, Rutledge FN. Second-look laparotomy in the management of malignant germ cell tumors of the ovary. Obstet Gynecol. 1986;67:789–793
  68. Bekaii-Saab T, Einhorn LH, Williams SD. Late relapse of ovarian dysgerminoma: case report and literature review. Gynecol Oncol. 1999;72:111–112
  69. Balat O, Kudelka AP, Edward CL, Verschraegen C, Kavanagh JJ. Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature. Eur J Gynaecol Oncol. 1996;17:342–344
  70. Li J, Yang W, Wu X. Prognostic factors of role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. Gynecol Oncol. 2007;105:769–775
  71. Bower M, Newlands ES, Holden L, Rustin GJ, Begent RH. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol. 1997;8:477–483
  72. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, et al. The German Testicular Cancer Study Group High-dose treatment with carboplatin, etoposide, and ifosfomide followed by autologous stem-cell transplantation in relapse or refractory germ cell cancer: a phase I/II study. J Clin Oncol. 1994;12:1223–1231
  73. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapse testicular germ cell cancer. J Clin Oncol. 2000;18:2413–2418
  74. Shamash J, Oliver RT, Ong J, Raja M, Edmonds P, Gallager CJ, et al. Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy. Ann Oncol. 1999;10:685–692
  75. Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutzvangwa K, et al. GAMEC—a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumors. Br J Cancer. 2001;97:308–314
  76. Hardy RD, Bell JG, Nicely CL, Reid GC. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: a case report and review of the literature. Gynecol Oncol. 2005;96:865–869
  77. Freeman SA, Modesitt SC. Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. Gynecol Oncol. 2006;103:755–758
  78. Finan MA, Roberts WS, Kavanagh JJ. Ovarian Sertoli-Leydig cell tumor: success with salvage therapy. Int J Gynecol Cancer. 1993;3:189–191

PII: S0093-7754(08)00261-3

doi: 10.1053/j.seminoncol.2008.12.004

Seminars in Oncology
Volume 36, Issue 2 , Pages 126-136 , April 2009

Article Tools